Nervgen Pharma Corp. SEC filings NGEN
Nervgen Pharma Corp. has 41 filings in SEC EDGAR's recent list, going back to Sep 20, 2018. Its latest annual report, Form 40-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 25, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K/A | Form 6-k/a | Oct 16, 2026 | Aug 13, 2026 |
| 40-F/A | Amended annual report (Canadian issuer) | Oct 16, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Sep 25, 2026 | Sep 25, 2026 |
| 6-K | Current report (foreign issuer) | Sep 24, 2026 | Sep 24, 2026 |
| 6-K | Current report (foreign issuer) | Aug 13, 2026 | Aug 13, 2026 |
| 6-K | Current report (foreign issuer) | Jul 2, 2026 | Jul 2, 2026 |
| SUPPL | Filing | Jul 2, 2026 | — |
| 6-K | Current report (foreign issuer) | Jun 1, 2026 | Jun 1, 2026 |
| EFFECT | Filing | May 26, 2026 | — |
| 6-K | Current report (foreign issuer) | May 26, 2026 | May 26, 2026 |
| SUPPL | Filing | May 26, 2026 | — |
| F-X | Form f-x | May 26, 2026 | — |
| F-10 | Filing | May 26, 2026 | — |
| 6-K | Current report (foreign issuer) | May 22, 2026 | May 22, 2026 |
| SUPPL | Filing | May 22, 2026 | — |
| SUPPL | Filing | May 21, 2026 | — |
| 6-K | Current report (foreign issuer) | May 18, 2026 | May 18, 2026 |
| 6-K | Current report (foreign issuer) | May 15, 2026 | May 15, 2026 |
| S-8 | Employee stock plan registration | May 7, 2026 | — |
| 6-K | Current report (foreign issuer) | Apr 27, 2026 | Apr 27, 2026 |
| 40-F | Annual report (Canadian issuer) | Mar 31, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Mar 13, 2026 | Mar 13, 2026 |
| 6-K | Current report (foreign issuer) | Feb 13, 2026 | Feb 13, 2026 |
| 6-K | Current report (foreign issuer) | Feb 10, 2026 | Feb 10, 2026 |
| S-8 | Employee stock plan registration | Jan 23, 2026 | — |
| 6-K | Current report (foreign issuer) | Jan 8, 2026 | Jan 8, 2026 |
| EFFECT | Filing | Jan 7, 2026 | — |
| CERT | Filing | Jan 7, 2026 | — |
| 8-A12B | Filing | Jan 7, 2026 | — |
| F-10/A | Filing | Jan 7, 2026 | — |
| F-X | Form f-x | Dec 17, 2025 | — |
| F-10 | Filing | Dec 17, 2025 | — |
| D | Filing | Dec 14, 2021 | — |
| D/A | Filing | Aug 25, 2021 | — |
| D | Filing | Aug 17, 2021 | — |
| D/A | Filing | Jun 2, 2021 | — |
| D | Filing | Aug 25, 2020 | — |
| D | Filing | Jun 3, 2020 | — |
| D | Filing | Nov 22, 2019 | — |
| D | Filing | Mar 21, 2019 | — |
| D | Filing | Sep 20, 2018 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NGEN (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Vancouver
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1751912
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.